Therapeutic AZO-compounds for drug delivery

a technology of azocompounds and drugs, applied in the direction of medical preparations, pharmaceutical non-active ingredients, etc., can solve the problems of rash, nausea and vomiting, carrier molecule of this component is associated with several side effects,

Inactive Publication Date: 2004-03-04
RUTGERS THE STATE UNIV
View PDF1 Cites 19 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the carrier molecule for this component is associated with several side effects such as nausea and vomiting, rash, or other severe toxic reactions.
However, this drug causes several objectionable side effects.
The side effects that makes this drug intolerable to patients, however, are the gastrointestinal reactions.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic AZO-compounds for drug delivery
  • Therapeutic AZO-compounds for drug delivery
  • Therapeutic AZO-compounds for drug delivery

Examples

Experimental program
Comparison scheme
Effect test

example 2

[0108] In Example 2, Scheme 6 illustrates the synthesis of a poly(azo-anhydride) compound linking 4-ASA. The 4-aminosalicylic acid is converted to its methyl ester with sulfuric acid in methanol. Methyl-4-aminosalicylate is dimerized via azoxy linkage with hydrogen peroxide in acetic acid. The azoxy compound is reduced to the hydrazo compound with zinc dust in acetic acid. The hydrazo compound is oxidized to the azo compound with sodium perborate in acetic acid. The methyl esters are cleaved with alkali to give the prepolymer azo diacid. The diacid is converted to the activated monomer by refluxing in an excess of acetic anhydride. The monomer is then converted to the polyazo compound. 6

[0109] Activity

[0110] The ability of a polymer of the invention to produce a given therapeutic effect can be determined using in vitro and in vivo pharmacological models which are well known to the art.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
average molecular weightsaaaaaaaaaa
molecular weightsaaaaaaaaaa
Login to view more

Abstract

Polyazo compounds, which include low molecular weight drugs having a carboxylic acid group and an amine, thiol, alcohol or phenol group within their structure, formed into polymeric drug delivery systems are provided. Also provided are methods of producing polymeric drug delivery systems having these polyazo compounds as well as methods of administering low molecular weight drugs to a host via the polymeric drug delivery system.

Description

PRIORITY OF INVENTION[0001] This application claims priority from U.S. Provisional Patent Application No. 60 / 220,998, filed Jul. 27, 2000), which is incorporated herein by reference.[0002] 5-Aminosalicylic acid (5-ASA) is the active component of a commonly used treatment for inflammatory bowel disease (IBD) and Crohn's disease treatment. 5-ASA drug is typically linked via an azo bond to a carrier that allows for targeted drug release exclusively in the large intestine where the azo bond is cleaved by the indigenous bacteria. However, the carrier molecule for this component is associated with several side effects such as nausea and vomiting, rash, or other severe toxic reactions.[0003] 4-Aminosalicylic acid (4-ASA) has shown promise in the treatment of inflammatory bowel disease as well as tuberculosis. However, this drug causes several objectionable side effects. Some of the less common side effects are hepatitis, hypokalemia, acute renal failure, mild hypoprothrombinemia, hemolytic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K47/48
CPCA61K47/48192A61K47/48023A61K47/54A61K47/59
Inventor UHRICH, KATHRYN E.
Owner RUTGERS THE STATE UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap